Ki Ho Park

Dr. Ki Ho Park

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Ki Ho ParkKi Ho Park
Ki Ho Park
MCManish Chhowalla
Manish Chhowalla
ZIZafar Iqbal
Zafar Iqbal
FSFederico Sesti
Federico Sesti
Here we identify a novel class of biological membrane ion channel blockers called single-walled carbon nanotubes (SWNTs). SWNTs with diameter distributions peaked at ∼0.9 and 1.3 nm, C60 fullerenes, multi wall nanotubes (MWNTs), and hyperfullerenes (nano-“onions”) were synthesized by several techniques and applied to diverse channel types heterologously expressed in mammalian cells. External as-fabricated and purified SWNTs blocked K+ channel subunits in a dose-dependent manner. Blockage was dependent on the shape and dimensions of the nanoparticles used and did not require any electrochemical interaction. SWNTs were more effective than the spherical fullerenes and, for both, diameter was the determining factor. These findings postulate new uses for SWNTs in biological applications and provide unexpected insights into the current view of mechanisms governing the interaction of ion channels with blocking molecules.

11 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZBZehua Bian
Zehua Bian
QWQiang Wang
Qiang Wang
XZXinyu Zhou
Xinyu Zhou
TTTao Tan
Tao Tan
Ki Ho ParkKi Ho Park
Ki Ho Park
JMJianjie Ma
Jianjie Ma
MG53 is a muscle-specific TRIM-family protein that presides over the cell membrane repair response. Here, we show that MG53 present in blood circulation acts as a myokine to facilitate tissue injury-repair and regeneration. Transgenic mice with sustained elevation of MG53 in the bloodstream (tPA-MG53) have a healthier and longer life-span when compared with littermate wild type mice. The tPA-MG53 mice show normal glucose handling and insulin signaling in skeletal muscle, and sustained elevation of MG53 in the bloodstream does not have a deleterious impact on db/db mice. More importantly, the tPA-MG53 mice display remarkable dermal wound healing capacity, enhanced muscle performance, and improved injury-repair and regeneration. Recombinant human MG53 protein protects against eccentric contraction-induced acute and chronic muscle injury in mice. Our findings highlight the myokine function of MG53 in tissue protection and present MG53 as an attractive biological reagent for regenerative medicine without interference with glucose handling in the body.

17 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMatthew Sermersheim
Matthew Sermersheim
AKAdam D. Kenney
Adam D. Kenney
Pei-Hui LinPei-Hui Lin
Pei-Hui Lin
TMTemet M. McMichael
Temet M. McMichael
CCChuanxi Cai
Chuanxi Cai
JMJianjie Ma
Jianjie Ma
TRIM family proteins play integral roles in the innate immune response to virus infection. MG53 (TRIM72) is essential for cell membrane repair and is believed to be a muscle-specific TRIM protein. Here we show human macrophages express MG53, and MG53 protein expression is reduced following virus infection. Knockdown of MG53 in macrophages leads to increases in type I interferon (IFN) upon infection. MG53 knockout mice infected with influenza virus show comparable influenza virus titres to wild type mice, but display increased morbidity accompanied by more accumulation of CD45+ cells and elevation of IFNβ in the lung. We find that MG53 knockdown results in activation of NFκB signalling, which is linked to an increase in intracellular calcium oscillation mediated by ryanodine receptor (RyR). MG53 inhibits IFNβ induction in an RyR-dependent manner. This study establishes MG53 as a new target for control of virus-induced morbidity and tissue injury.

1 January 2022 in Molecular Therapy
Verified
Journal Article
Open access
LJLin Jiang
Lin Jiang
Jialiang LiangJialiang Liang
Jialiang Liang
WHWei Huang
Wei Huang
JMJianyong Ma
Jianyong Ma
Ki Ho ParkKi Ho Park
Ki Ho Park
Yigang WangYigang Wang
Yigang Wang
Fibroblasts can be reprogrammed into cardiovascular progenitor cells (CPCs) using transgenic approaches, although the underlying mechanism remains unclear. We determined whether activation of endogenous genes such as Gata4, Nkx2.5, and Tbx5 can rapidly establish autoregulatory loops and initiate CPC generation in adult extracardiac fibroblasts using a CRISPR activation system. The induced fibroblasts (>80%) showed phenotypic changes as indicated by an Nkx2.5 cardiac enhancer reporter. The progenitor characteristics were confirmed by colony formation and expression of cardiovascular genes. Cardiac sphere induction segregated the early and late reprogrammed cells that can generate functional cardiomyocytes and vascular cells in vitro. Therefore, they were termed CRISPR-induced CPCs (ciCPCs). Transcriptomic analysis showed that cell cycle and heart development pathways were important to accelerate CPC formation during the early reprogramming stage. The CRISPR system opened the silenced chromatin locus, thereby allowing transcriptional factors to access their own promoters and eventually forming a positive feedback loop. The regenerative potential of ciCPCs was assessed after implantation in mouse myocardial infarction models. The engrafted ciCPCs differentiated into cardiovascular cells in vivo but also significantly improved contractile function and scar formation. In conclusion, multiplex gene activation was sufficient to drive CPC reprogramming, providing a new cell source for regenerative therapeutics.

8 September 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
XWxiaoliang wang
xiaoliang wang
XLXiuchun Li
Xiuchun Li
HOHannah Ong
Hannah Ong
TTTao Tan
Tao Tan
Ki Ho ParkKi Ho Park
Ki Ho Park
JMJianjie Ma
Jianjie Ma
Aging is associated with chronic oxidative stress and inflammation that affect tissue repair and regeneration capacity. MG53 is a TRIM family protein that facilitates repair of cell membrane injury in a redox-dependent manner. Here, we demonstrate that the expression of MG53 was reduced in failing human hearts and aged mouse hearts, concomitant with elevated NF-κB activation. We evaluated the safety and efficacy of longitudinal, systemic administration of recombinant human MG53 (rhMG53) protein in aged mice. Echocardiography and pressure-volume loop measurements revealed beneficial effects of rhMG53 treatment in improving heart function of aged mice. Biochemical and histological studies demonstrated that the cardioprotective effects of rhMG53 are linked to suppression of NF-κB-mediated inflammation, reducing apoptotic cell death and oxidative stress in the aged heart. Repetitive administration of rhMG53 in aged mice did not have adverse effects on major vital organ functions. These findings support the therapeutic value of rhMG53 in treating age-related decline in cardiac function.

16 October 2005 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
SCShi-Qing Cai
Shi-Qing Cai
LHLeonardo Hernandez-Hernandez
Leonardo Hernandez-Hernandez
YWYi Wang
Yi Wang
Ki Ho ParkKi Ho Park
Ki Ho Park
FSFederico Sesti
Federico Sesti